• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
Home
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
Search Icon
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Research
  • Biotech
    • Clinical Data
    • Venture Capital
    • Deals
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending Topics
    • Cell & Gene Therapy
    • COVID-19
    • Emerging Biopharma
  • Podcasts
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events

lupus nephritis

Biotech

Kezar's lupus data spur hope for inflammatory drug

Kezar’s hopes for zetomipzomib as a catch-all drug for inflammatory disease may be over, but a phase 2 readout offers hope in lupus nephritis.
James Waldron Jun 28, 2022 8:50am

How a Seattle Genetics cancer drug could help lupus patients

Apr 9, 2020 8:35am

Aurinia soars as phase 3 lupus study hits primary endpoint

Dec 5, 2019 7:30am

Aurinia poaches CEO Peter Greenleaf from Cerecor

Apr 12, 2019 10:49am

A CAR-T approach to lupus

Mar 6, 2019 2:26pm

Another setback for AZ as lupus drug fails phase 3 test

Aug 31, 2018 9:20am
Home
  • Connect
    • The Team
    • Advertise
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2023 Questex LLC All rights reserved.
Terms of use
Privacy Policy